Research progress on microRNAs in Huntington's disease
10.12092/j.issn.1009-2501.2020.06.011
- VernacularTitle: microRNA在亨廷顿病中的研究进展
- Author:
Bingbing JIANG
1
Author Information
1. Faculty of Life Science and Technology, Kunming University of Science and Technology
- Publication Type:Journal Article
- Keywords:
Gene therapy;
Huntington's disease;
MicroRNA;
Regulation mechanism
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(6):677-685
- CountryChina
- Language:Chinese
-
Abstract:
Huntington's disease (HD) is a monogenic genetic disease of neurodegenerative disorders caused by repeated amplification of CAG trinucleotides in the first exon of the Huntingtin gene (HTT), and there are no treatments which could forestall or slow Huntington's disease. The protein product encoded by HTT is called huntingtin (Htt). The mutated huntingtin protein (mHtt) is easy to form aggregation which is toxic, leading to a series of cytological abnormalities and neuronal dysfunction. MicroRNA (miRNA) plays an important role in the post-transcriptional regulation of genes whose expression is related to the pathological process of Huntington's disease. miRNA is becoming the promising biomarker for the treatment of HD. Recent studies on the regulation of specific miRNAs in HD and the prediction of their target genes may provide a potential role for the treatment of HD. This review highlights the research progress on miRNAs in the occurrence of HD.
